Sage Therapeutics Inc SAGE

Sage Therapeutics Inc is an American clinical-stage biopharmaceutical company engaged in the discovery and development of novel therapies aimed at treating people with debilitating brain and central nervous system (CNS) disorders. The company is developing treatments for a range of depressive, neurological, and neuropsychiatric disorders. Operating globally, the firm was founded in 2010 and is based in Cambridge, Massachusetts.

The focus of the firm’s research and development is on modulation of two critical neurotransmitter systems: GABA and NMDA receptors. These systems are the major signalling pathways of the brain and central nervous system, and it is understood that both contribute significantly to regulating CNS function. Eliminating dysfunction in these two systems is potentially the key to effectively treating numerous conditions, including depressive disorders.

The firm’s product Zulresso is a prescription medication for the treatment of new mothers suffering from post-partum depression. Other treatments in the Sage Therapeutics pipeline are aimed at addressing treatment-resistant depression, generalised anxiety disorder, bipolar disorder, Alzheimer’s disease, and the cognitive dysfunction associated with Parkinson’s disease. The firm publicly trades on the NASDAQ, where it is listed under the stock ticker SAGE.

Start monitoring Sage Therapeutics Inc value changes by adding SAGE stock to your eToro watchlist.